Bristol Myers Squibb Co
CELG.RI- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000014272
In the last 90 days, Bristol Myers Squibb Co insiders filed 0 open-market purchases and 2 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesBMY
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $437.2K in total
- 2
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CELG.RI, Q2 2026
No superinvestor reported holding CELG.RI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Bristol Myers Squibb Co insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)4:37 PM ET | Sep 9 | 1 day | Massacesi CristianEVP,Chief Med Offr,Head of Dev | SSaleCommon Stock, $0.10 par value | −6.25K | $64.57 | −$403.5K | −25.0%18.7K after | |
| Aug 26, 2026 (view filing)4:17 PM ET | Aug 25 | 1 day | Holzer Phil MSVP and Controller | SSaleCommon Stock, $0.10 par value | −500 | $67.50 | −$33.8K | −2.9%16.9K after | |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Elkins David VEVP, Chief Financial Officer | SSaleCommon Stock, $0.10 par value | −30.0K | $61.67 | −$1.85M | −15.9%159.2K after | 2 lots |
| Sep 3, 2025 (view filing) | Sep 2 | 1 day | Elkins David VEVP, Chief Financial Officer | SSaleCommon Stock, $0.10 par value | −56.0K | $47.33 | −$2.65M | −25.1%167.4K after | |
| Aug 5, 2025 (view filing) | Aug 2 | 3 days | Short Bartie WendyEVP, Corporate Affairs | SSaleCommon Stock, $0.10 par value | −378 | $44.23 | −$16.7K | −6.9%5.07K after | |
| May 13, 2025 (view filing) | May 9 | 4 days | Hickey BenjaminPresident, RayzeBio Org. | SSaleCommon Stock, $0.10 par value | −97.39 | $38.01 | −$3.70K | −100.0%0 after | |
| Apr 29, 2025 (view filing) | Apr 25 | 4 days | Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. | PPurchaseCommon Stock, $0.10 par value | +4.25K | $47.58 | +$202.2K | +5.4%83.5K after | |
| Feb 21, 2025 (view filing) | Feb 20 | 1 day | Boerner Christopher S.Chief Executive Officer | PPurchaseCommon Stock, $0.10 par value | +2.00K | $55.05 | +$110.1K | +1.9%104.6K after | |
| Feb 19, 2025 (view filing) | Feb 14 | 5 days | Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. | PPurchaseCommon Stock, $0.10 par value | +1.82K | $54.84 | +$100.0K | +2.9%63.9K after | |
| Nov 5, 2024 (view filing) | Nov 4 | 1 day | Holzer Phil MSVP and Controller | SSaleCommon Stock, $0.10 par value | −700 | $55.62 | −$38.9K | −5.6%11.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Bristol Myers Squibb Co at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding CELG.RI in 13F filings for Q2 2026.